Pfizer's Trading Volume Surges 116.9% to $1.328 Billion, Ranks 89th in Daily Volume

On May 30, 2025, Pfizer's trading volume reached $1.328 billion, marking an 116.9% increase from the previous day. This surge placed Pfizer at the 89th position in terms of trading volume for the day. Pfizer's stock price rose by 0.17%, marking the second consecutive day of gains, with a total increase of 1.34% over the past two days.

Pfizer has terminated its partnership with Acepodia, a move that comes amidst ongoing legal challenges related to Depo-Provera. The decision to end the collaboration, which focused on the development of autoimmune disease drugs, was driven by Pfizer's global resource prioritization rather than any issues with Acepodia's capabilities. Both companies have left the door open for potential future collaborations.

In addition to the partnership termination, Pfizer is facing significant legal scrutiny over Depo-Provera. The company is involved in multidistrict litigation with approximately 400 lawsuits alleging that Pfizer failed to adequately warn about the risk of brain tumors associated with long-term use of the contraceptive. Recent studies have intensified the scrutiny, and hearings are scheduled as the company faces accusations of prioritizing profits over patient safety.